MedTrace Logo

CytoSorb® in Patients With Acute on Chronic Liver Failure

NCT05131230 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-11-29

No results posted yet for this study

Summary

The objective of this study is to assess the safety and performance of the CytoSorb® therapy in patients with Acute on Chronic Liver Failure (ACLF) grade ≥ 2 due to a severe alcohol induced hepatitis (Maddrey DF \> 32) and a severe inflammatory response.

Conditions

  • Acute on Chronic Liver Failure
  • Alcoholic Hepatitis

Interventions

DEVICE

CytoSorb® treatment

Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.

Sponsors & Collaborators

  • CytoSorbents Europe GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2023-03-31
Completion
2023-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05131230 on ClinicalTrials.gov